Follow-up vs. chemo after surgery for early stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stomach or gastroesophageal junction (GEJ) adenocarcinoma that is stage IB or IIA (not T2N1).
- You have had surgery to remove the tumor, and it was considered curative.
- Your overall health is good enough for treatment (ECOG score 0–2).
- Your blood tests and organ functions meet the study's requirements (kidney, liver, blood counts, etc.).
- You have not had other cancer treatments (except the surgery) and have no other recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether giving extra treatment after surgery for stomach cancer can help lower the chance of it coming back. It is for people who had a specific kind of chemotherapy and immunotherapy before surgery and then had their stomach removed.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial tests whether skipping chemotherapy after surgery is safe and effective for some patients with gastric cancer. If your tumor responded very well or very poorly to the pre-surgery chemotherapy, you might be able to avoid more chemo.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Hear when a new Stage IB-IIA Adenocarcinoma of the Stomach or Gastroesophageal Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.